一项在未行全膀胱切除术的肌层浸润性膀胱尿路上皮癌(MIBC)受试者中评估TAR-200与Cetrelimab联合给药对比同期放化疗的疗效的III期、多中心、随机研究
[Translation] A phase III, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in subjects with muscle-invasive bladder urothelial carcinoma (MIBC) without total cystectomy
比较接受TAR-200与Cetrelimab联合给药和接受同期放化疗的受试者的BI-EFS
[Translation] Comparison of BI-EFS in subjects receiving TAR-200 in combination with cetrelimab and concurrent chemoradiotherapy
一项在慢性肾脏病(CKD)伴高钾血症或存在高钾血症风险的受试者中评价环硅酸锆钠对CKD进展的作用的国际、随机、双盲、安慰剂对照3 期研究
[Translation] An international, randomized, double-blind, placebo-controlled phase 3 evaluation of sodium zirconium cyclosilicate on the progression of CKD in subjects with chronic kidney disease (CKD) with or at risk for hyperkalemia Research
1. 主要目的:确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在减缓CKD 进展方面是否优效于安慰剂
2. 次要目的:
a. 确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在降低复合终点肾衰竭结果的发生率方面是否优效于安慰剂
b. 确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在降低随机分组时接受赖诺普利/缬沙坦治疗的受试者中减少赖诺普利/缬沙坦剂量的发生率方面是否优效于安慰剂
c. 确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在减少白蛋白尿方面是否优效于安慰剂
d. 确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在增加血清碳酸氢盐水平方面是否优效于安慰剂
e. 确定SZC 作为ACEi/ARB 治疗的辅助治疗时,在维持正常血钾水平方面是否优效于安慰剂
3. 安全性目的
评估SZC 作为ACEi/ARB 治疗的辅助治疗相较于安慰剂的安全性和耐受性
[Translation] 1. Primary objective: To determine whether SZC is superior to placebo in slowing CKD progression as adjunctive therapy to ACEi/ARB therapy
2. Secondary purpose:
a. To determine whether SZC is superior to placebo in reducing the incidence of composite renal failure outcomes when used as adjunctive therapy to ACEi/ARB therapy
b. To determine whether SZC is superior in reducing the incidence of lisinopril/valsartan dose reduction in subjects receiving lisinopril/valsartan at randomization when used as adjunctive therapy to ACEi/ARB therapy placebo
c. To determine whether SZC is superior to placebo in reducing albuminuria when used as adjunctive therapy to ACEi/ARB therapy
d. To determine whether SZC is superior to placebo in increasing serum bicarbonate levels when used as adjunctive therapy to ACEi/ARB therapy
e. To determine whether SZC is superior to placebo in maintaining normokalemia when used as adjunctive therapy to ACEi/ARB therapy
3. Security Purposes
To evaluate the safety and tolerability of SZC as adjunctive therapy to ACEi/ARB therapy compared to placebo
亿珂在中国慢性淋巴细胞白血病或小淋巴细胞淋巴瘤初治患者中的治疗模式和治疗反应:一项真实世界数据库的研究
[Translation] Treatment patterns and treatment response of Yike in Chinese patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a real-world database study
根据国际慢性淋巴细胞白血病工作组(iwCLL)共识指南,估算伊布替尼在CLL/SLL初治患者中的总体反应率(ORR)。
[Translation] The overall response rate (ORR) of ibrutinib in CLL/SLL-naïve patients was estimated according to the International Chronic Lymphocytic Leukemia Working Group (iwCLL) consensus guidelines.
100 Clinical Results associated with AndersonBrecon, Inc.
0 Patents (Medical) associated with AndersonBrecon, Inc.
100 Deals associated with AndersonBrecon, Inc.
100 Translational Medicine associated with AndersonBrecon, Inc.